Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Operating Expenses: 2022-2025

Historic Other Operating Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Sep 2025 value amounting to -$515,000.

  • Orchestra BioMed Holdings' Other Operating Expenses fell 156.22% to -$515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $137,000, marking a year-over-year decrease of 94.33%. This contributed to the annual value of $3.3 million for FY2024, which is 37.34% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Other Operating Expenses of -$515,000 as of Q3 2025, which was down 1,330.56% from -$36,000 recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Other Operating Expenses high stood at $1.2 million for Q3 2023, and its period low was -$601,000 during Q1 2022.
  • Its 3-year average for Other Operating Expenses is $479,818, with a median of $605,000 in 2023.
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Other Operating Expenses was 661.86% (2023), while the steepest drop was 532.05% (2023).
  • Over the past 4 years, Orchestra BioMed Holdings' Other Operating Expenses (Quarterly) stood at $78,000 in 2022, then slumped by 532.05% to -$337,000 in 2023, then soared by 254.90% to $522,000 in 2024, then crashed by 156.22% to -$515,000 in 2025.
  • Its Other Operating Expenses was -$515,000 in Q3 2025, compared to -$36,000 in Q2 2025 and $166,000 in Q1 2025.